

MARKET REPORT



Thalassemia Market, By Thalassemia Type (Alpha and Beta), By Therapeutic Class (Iron Chelating Drugs, Blood Transfusion, Gene Therapy, Folic Acid Supplements), By End Use (Hospital, Laboratories, Research Institute, Clinics), and By Geography (EU, NA, APAC, LATAM, and MEA) – Analysis, Size, Share, Trends, & Forecast from 2020-2026

BioPortfolio

Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



AnalystView
Market Insights

Thalassemia Market, By Thalassemia Type (Alpha and Beta), By Therapeutic Class (Iron Chelating Drugs, Blood Transfusion, Gene Therapy, Folic Acid Supplements), By End Use (Hospital, Laboratories, Research Institute, Clinics), and By Geography (EU, NA, APAC, LATAM, and MEA) – Analysis, Size, Share, Trends, & Forecast from 2020-2026

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** bioportfolio97@gmail.com

Thalassemia Market, By Thalassemia Type (Alpha and Beta), By Therapeutic Class (Iron Chelating Drugs, Blood Transfusion, Gene Therapy, Folic Acid Supplements), By End Use (Hospital, Laboratories, Research Institute, Clinics), and By Geography (EU, NA, APAC, LATAM, and MEA) – Analysis, Size, Share, Trends, & Forecast from 2020-2026

REPORT HIGHLIGHT

Thalassemia market was valued at USD 2.48 billion by 2019, growing with 9.7% CAGR during the forecast period, 2020-2026.

Thalassemia is an inherited or genetic blood disorder, which is characterized by the abnormal production of hemoglobin present in the blood cells of the human body. Hemoglobin is the protein that functions to carry oxygen all through the human body, which results in the annihilation of the blood cells leading to anemia.

Market Dynamics

The increasing population, growing demand for enhanced curative gene therapies, and rising awareness regarding available treatment options are the major factors boosting the growth of the global thalassemia market. According to the World Health Organization (WHO), approximately 4.4 every 10,000 live births are affected by thalassemia all across the globe. And, about 5% of the total world population has a variation in the beta or alpha part of the hemoglobin molecule. Furthermore, a surge in the development of pipeline drugs and novel therapies coupled with research & development is another factor propelling the market growth. However, high costs and the lack of viable treatment options associated with the disease are predicted to restrict the market growth in the coming future. On the contrary, the growing investments in healthcare by governments and various key players are expected to create lucrative growth opportunities in the overall market during the forecast period.

Thalassemia Type Takeaway

“Alpha thalassemia segment to witness the fastest growth during the forecast period”

Based on the thalassemia type, the global market is bifurcated into alpha-thalassemia and beta-thalassemia. Of these, the alpha thalassemia segment is estimated to grow at the fastest rate during the forecast period mainly because it is one of the most common autosomal disorders. The growing prevalence of alpha-globin disorders in the U.S. and other western countries is impelling the segmental market growth. In addition, the prevalence of alpha thalassemia is more as compared to the beta-thalassemia, which will fuel the growth of the alpha-thalassemia segment during the forecast period. On the other hand, the beta-thalassemia segment is projected to witness significant growth during the period of forecast. According to the WHO, around 1.5% of the worldwide population is affected by beta-thalassemia.

Therapeutic Class Takeaway

“Blood transfusion segment is anticipated to dominate the industry by 2026”

On the basis of therapeutic class, the overall market for thalassemia is categorized into iron chelating drugs, blood transfusion, folic acid supplements, and gene therapy. The iron-chelating drugs and the gene therapy segment are further sub-categorized into exjade/jadenu (deferasirox) and lentiglobin respectively. Among these, the blood transfusion segment accounted for the largest market share in 2019 and is expected to dominate the industry during the forecast period. This dominance is majorly attributed to the low risk involved in blood transfusion treatment due to careful blood screening. In addition, this treatment has a high success rate compared to other treatments, which makes it most preferable by patients. This will contribute to the segmental market growth in the projected timeframe.

On the other hand, the gene therapy segment is estimated to grow at a considerable rate during the forecast period as it has the potential to change the thalassemia treatment landscape amidst regulatory uncertainties and major clinical development challenges. In addition, scientists are involved in investigating several genetic techniques for the treatment of thalassemia.

Pipeline Products Takeaway

Gene therapy is considered to be the forefront of emerging curative therapies for thalassemia condition, with several genomic molecules under late stage clinical studies. Some of the key players' have already initiated phase III trials for this condition while many are in preclinical evaluation. Recently, a new approach of gene editing for the correction of beta-globin mutation or disruption of the BCL11A gene has been initiated to increase fetal hemoglobin production. This molecule is expected to achieve the preclinical stage soon.

Furthermore, gene correction of autologous hematopoietic stem cells using Lentiviral vectors has been successfully established with a projected launch in the market by 2022. Even though curative possibilities for this disease is expanding, making it accessible to a larger number of patients on a global level remains a challenge.

End Use Takeaway

“Hospital segment to be most lucrative in the forecast period”

Based on end-use, the worldwide thalassemia market is classified into a hospital, research institute, laboratories, and clinics. Among these, the hospital segment accounted for the majority of share in the market in 2009 and is projected to lead the market during the forecast period. This is primarily owing to growth in the number of admissions in hospitals for thalassemia treatment. In addition, the growing prevalence of thalassemia is also likely to drive the segmental market growth. On the other hand, the laboratories segment is expected to hold a significant share in the market throughout the forecast owing to growing awareness amongst people regarding thalassemia treatment.

Regional Takeaway

“North America region to hold a significant market share by 2026”

Depending on the region, the global industry is divided into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. The North America thalassemia market held the highest market share in 2019 and is expected to grow at a significant rate during the period of forecast. This is majorly owing to increasing awareness of thalassemia and the rising incidence of alpha thalassemia in this region.

Moreover, the increased effort by the government in various countries of the North America region to support gene therapy is another responsible for the regional market growth. On the other hand, the Asia Pacific market for thalassemia is expected to grow at the fastest CAGR owing to increasing investments by governments in healthcare infrastructure.

COVID-19 Impact

The worldwide spread of COVID-19 disease has adversely affected the global thalassemia market. Multiple challenges are being faced by the market such as unavailability of blood in blood banks, transfusion facilities, and transportation for the treatment of thalassemia disorders. Moreover, the overall market is likely to recover at a slow rate post the COVID-19 pandemic.

Key Vendor Takeaway

The leading players of the global thalassemia market include Bluebird Bio, ApoPharmaInc, Sangamo Bioscience, Bellicum Pharmaceuticals, Pfizer, Inc., AcceleronPharma / Celgene Corporation, Novartis, KiadisPharma. These players are involved in R&D activities to develop an improved treatment for thalassemia to hold a strong position in the global industry. Companies are involved in developing new products for the disease treatment. For instance, recently, in January 2020, Bluebird Bio launched its first beta thalassemia gene therapy namely, 'Zynteglo' in Germany. A German manufacturer, apceth Biopharma is recruited by the company to produce Zynteglo.

The market size and forecast for each segment and sub-segments has been considered as below:

Historical Year - 2015 to 2018

Base Year - 2019

Estimated Year - 2020

Projected Year - 2026

TARGET AUDIENCE

Traders, Distributors, and Suppliers

Manufacturers

Government and Regional Agencies

Research Organizations

Consultants

Distributors

SCOPE OF THE REPORT

<https://www.bioportfolio.co.uk/product/270627>
bioportfolio97@gmail.com to order

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL THALASSEMIA MARKET KEY PLAYERS

AcceleronPharma / Celgene Corporation

Novartis AG

Bluebird Bio

ApoPharmaInc

Sangamo Bioscience

Bellicum Pharmaceuticals

Pfizer, Inc.

KiadisPharma

GLOBAL THALASSEMIA MARKET, BY THALASSEMIA TYPE

Alpha Thalassemia

Beta Thalassemia

GLOBAL THALASSEMIA MARKET, BY THERAPEUTIC CLASS

Gene Therapy

LentiGlobin

Iron Chelating Drugs

Exjade/Jadenu (deferasirox)

Blood Transfusions

Folic Acid Supplements

GLOBAL THALASSEMIA MARKET, BY END-USE

Research Institutes

Hospital

Laboratories

Clinics

Others

GLOBAL THALASSEMIA MARKET, BY REGION

North America

The U.S.

Canada

Europe

Germany

France

Italy

Spain

United Kingdom

Rest of Europe

Asia Pacific

India

China

South Korea

Japan

Singapore

Rest of APAC

Latin America

Brazil

Mexico

Argentina

Rest of LATAM

Middle East and Africa

Saudi Arabia

United Arab Emirates

Rest of MEA

Additional Details

Publisher : AnalystView

Reference : AV637

Number of Pages : 188

Report Format : PDF

Publisher Information :



AnalystView Market Insights is a market research and consulting firm that adopts a proactive approach to provide the diverse need for accurate and precise market research, custom research, and consulting solutions across geographies and industry verticals. Our company is led by a team of passionate, naturally curious, and strategic thinkers from different industry backgrounds.

These experts are dedicated to creating concrete market data analysis in various industries such as Healthcare, Bulk Chemicals, Semiconductors and Electronics, Foods and Beverages. We strive to develop meaningful and evidence-based research data that helps our clients, empowering organizations and brands of all sizes with strategic analysis, accurate data, and consumer trends.

We aim to be the number one choice for various clients who require credible data to make vital business decisions. We wish to be a trusted and reliable analytics partner to major business organizations.

We understand that critical business decisions can be taken only when verified, authentic information is available. Therefore, our experts work meticulously to provide our clients with the accurate data, so that they need not spend time in verifying it.

It is also our goal to help our clients ignore traditional research methods that require a large amount of capital, manpower, and most important of it all – the time. We know that these factors are precious to a company and always follow the latest research techniques that produce the required result in a short span of time.

Table Of Contents for Thalassemia Market, By Thalassemia Type (Alpha and Beta), By Therapeutic Class (Iron Chelating Drugs, Blood Transfusion, Gene Therapy, Folic Acid Supplements), By End Use (Hospital, Laboratories, Research Institute, Clinics), and By Geography (EU, NA, APAC, LATAM, and MEA) – Analysis, Size, Share, Trends, & Forecast from 2020-2026

- TABLE OF CONTENT1. THALASSEMIA MARKET OVERVIEW1.1. Study Scope1.2. Assumption and Methodology2. EXECUTIVE SUMMARY2.1. Market Snippet2.1.1. Market Snippet by Thalassemia Type2.1.2. Market Snippet by Therapeutic Class2.1.3. Market Snippet by End Use2.1.4. Market Snippet by Region2.2. Competitive Insights3. THALASSEMIA KEY MARKET TRENDS3.1. Market Drivers3.1.1. Impact Analysis of Market Drivers3.2. Market Restraints3.2.1. Impact Analysis of Market Restraints3.3. Market Opportunities3.4. Market Future Trends4. THALASSEMIA INDUSTRY STUDY4.1. Porter’s Five Forces Analysis4.2. Marketing Strategy Analysis4.3. Growth Prospect Mapping4.4. Regulatory Framework Analysis4.5. COVID-19 Impact Analysis4.5.1. Pre-COVID-19 Impact Analysis4.5.2. Post-COVID-19 Impact Analysis5. THALASSEMIA MARKET LANDSCAPE5.1. Market Share Analysis5.2. Key Innovators5.3. Breakdown Data, by Key manufacturer5.3.1. Established Player Analysis5.3.2. Emerging Player Analysis6. THALASSEMIA MARKET – BY THALASSEMIA TYPE6.1. Overview6.1.1. Segment Share Analysis, By Thalassemia Type, 2019 & 2026 (%)6.2. Alpha Thalassemia6.2.1. Overview6.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US\$ Million)6.3. Beta Thalassemia6.3.1. Overview6.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US\$ Million)7. THALASSEMIA MARKET – BY THERAPEUTIC CLASS7.1. Overview7.1.1. Segment Share Analysis, By Thalassemia Type, 2019 & 2026 (%)7.2. Gene Therapy7.2.1. Overview7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US\$ Million)7.2.2.1. LentiGlobin7.2.2.1.1. Overview7.2.2.1.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US\$ Million)7.3. Iron Chelating Drugs7.3.1. Overview7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US\$ Million)7.3.2.1. Exjade/Jadenu (deferasirox)7.3.2.1.1. Overview7.3.2.1.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US\$ Million)7.4. Blood Transfusions7.4.1. Overview7.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US\$ Million)7.5. Folic Acid Supplements7.5.1. Overview7.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US\$ Million)8. THALASSEMIA MARKET – BY END USE8.1. Overview8.1.1. Segment Share Analysis, By End Use, 2019 & 2026 (%)8.2. Hospital8.2.1. Overview8.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US\$ Million)8.3. Laboratories8.3.1. Overview8.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US\$ Million)8.4. Research Institutes8.4.1. Overview8.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US\$ Million)8.5. Clinics8.5.1. Overview8.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US\$ Million)9. THALASSEMIA MARKET- BY GEOGRAPHY9.1. Introduction9.1.1. Segment Share Analysis, By Region, 2019 & 2026 (%)9.2. North America9.2.1. Overview9.2.2. Key Manufacturers in North America9.2.3. North America Market Size and Forecast, By Country, 2015 – 2026 (US\$ Million)9.2.4. North America Market Size and Forecast, By Thalassemia Type, 2015 – 2026 (US\$ Million)9.2.5. North America Market Size and Forecast, By Therapeutic Class, 2015 – 2026 (US\$ Million)9.2.6. North America Market Size and Forecast, By End Use, 2015 – 2026 (US\$ Million)9.2.7. U.S.9.2.7.1. Overview9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US\$ Million)9.2.8. Canada9.2.8.1. Overview9.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US\$ Million)9.3. Europe9.3.1. Overview9.3.2. Key Manufacturers in Europe9.3.3. Europe Market Size and Forecast, By Country, 2015 – 2026 (US\$ Million)9.3.4. Europe Market Size and Forecast, By Thalassemia Type, 2015 – 2026 (US\$ Million)9.3.5. Europe Market Size and Forecast, By Therapeutic Class, 2015 – 2026 (US\$ Million)9.3.6. Europe Market Size and Forecast, By End Use, 2015 – 2026 (US\$ Million)9.3.7. Germany9.3.7.1. Overview9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US\$ Million)9.3.8. Italy9.3.8.1. Overview9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US\$ Million)9.3.9. United Kingdom9.3.9.1. Overview9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US\$ Million)9.3.10. France9.3.10.1. Overview9.3.10.2. Market

Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US\$ Million)9.3.11. Rest of Europe9.3.11.1. Overview9.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US\$ Million)9.4. Asia Pacific (APAC)9.4.1. Overview9.4.2. Key Manufacturers in Asia Pacific9.4.3. Asia Pacific Market Size and Forecast, By Country, 2015 – 2026 (US\$ Million)9.4.4. Asia Pacific Market Size and Forecast, By Thalassemia Type, 2015 – 2026 (US\$ Million)9.4.5. Asia Pacific Market Size and Forecast, By Therapeutic Class, 2015 – 2026 (US\$ Million)9.4.6. Asia Pacific Market Size and Forecast, By End Use, 2015 – 2026 (US\$ Million)9.4.7. India9.4.7.1. Overview9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US\$ Million)9.4.8. China9.4.8.1. Overview9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US\$ Million)9.4.9. Japan9.4.9.1. Overview9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US\$ Million)9.4.10. South Korea9.4.10.1. Overview9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US\$ Million)9.4.11. Rest of APAC9.4.11.1. Overview9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US\$ Million)9.5. Latin America9.5.1. Overview9.5.2. Key Manufacturers in Latin America9.5.3. Latin America Market Size and Forecast, By Country, 2015 – 2026 (US\$ Million)9.5.4. Latin America Market Size and Forecast, By Thalassemia Type, 2015 – 2026 (US\$ Million)9.5.5. Latin America Market Size and Forecast, By Therapeutic Class, 2015 – 2026 (US\$ Million)9.5.6. Latin America Market Size and Forecast, By End Use, 2015 – 2026 (US\$ Million)9.5.7. Brazil9.5.7.1. Overview9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US\$ Million)9.5.8. Mexico9.5.8.1. Overview9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US\$ Million)9.5.9. Argentina9.5.9.1. Overview9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US\$ Million)9.5.10. Rest of LATAM9.5.10.1. Overview9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US\$ Million)9.6. Middle East and Africa9.6.1. Overview9.6.2. Key Manufacturers in Middle East and Africa9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2015 – 2026 (US\$ Million)9.6.4. Middle East and Africa Market Size and Forecast, By Thalassemia Type, 2015 – 2026 (US\$ Million)9.6.5. Middle East and Africa Market Size and Forecast, By Therapeutic Class, 2015 – 2026 (US\$ Million)9.6.6. Middle East and Africa Market Size and Forecast, By End Use, 2015 – 2026 (US\$ Million)9.6.7. Saudi Arabia9.6.7.1. Overview9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US\$ Million)9.6.8. United Arab Emirates9.6.8.1. Overview9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US\$ Million)10. KEY VENDOR ANALYSIS10.1. Bluebird Bio10.1.1. Company Snapshot10.1.2. Financial Performance10.1.3. Thalassemia Type Benchmarking10.1.4. Strategic Initiatives10.2. ApoPharmaInc10.3. Sangamo Bioscienc10.4. Bellicum Pharmaceuticals10.5. Pfizer, Inc.10.6. AcceleronPharma / Celgene Corporation10.7. Novartis AG10.8. KiadisPharma11. 360 DEGREE ANALYSTVIEW12. APPENDIX12.1. Research Methodology12.2. References12.3. Abbreviations12.4. Disclaimer12.5. Contact Us

List Of Tables in Thalassemia Market, By Thalassemia Type (Alpha and Beta), By Therapeutic Class (Iron Chelating Drugs, Blood Transfusion, Gene Therapy, Folic Acid Supplements), By End Use (Hospital, Laboratories, Research Institute, Clinics), and By Geography (EU, NA, APAC, LATAM, and MEA) – Analysis, Size, Share, Trends, & Forecast from 2020-2026

List of Tables

TABLE List of data sources

TABLE Market drivers; Impact Analysis

TABLE Market restraints; Impact Analysis

TABLE Thalassemia market: End Usenapshot (2018)

TABLE Segment Dashboard; Definition and Scope, by Thalassemia Type

TABLE Global Thalassemia market, by Thalassemia Type 2015-2026 (USD Million)

TABLE Thalassemia market: Therapeutic Class Snapshot (2018)

TABLE Segment Dashboard; Definition and Scope, by Therapeutic Class

TABLE Global Thalassemia market, by Therapeutic Class 2015-2026 (USD Million)

TABLE Thalassemia market: End UseSnapshot (2018)

TABLE Segment Dashboard; Definition and Scope, by End Use

TABLE Global Thalassemia market, by End Use2015-2026 (USD Million)

TABLE Thalassemia market: Regional Snapshot (2018)

TABLE Segment Dashboard; Definition and Scope, by Region

TABLE Global Thalassemia market, by Region 2015-2026 (USD Million)

TABLE North America Thalassemia market, by Country, 2015-2026 (USD Million)

TABLE North America Thalassemia market, by Thalassemia Type, 2015-2026 (USD Million)

TABLE North America Thalassemia market, by Therapeutic Class, 2015-2026 (USD Million)

TABLE North America Thalassemia market, by End Use, 2015-2026 (USD Million)

TABLE Europe Thalassemia market, by Country, 2015-2026 (USD Million)

TABLE Europe Thalassemia market, by Thalassemia Type, 2015-2026 (USD Million)

TABLE Europe Thalassemia market, by Therapeutic Class, 2015-2026 (USD Million)

TABLE Europe Thalassemia market, by End Use, 2015-2026 (USD Million)

TABLE Asia Pacific Thalassemia market, by Country, 2015-2026 (USD Million)

TABLE Asia Pacific Thalassemia market, by Thalassemia Type, 2015-2026 (USD Million)

TABLE Asia Pacific Thalassemia market, by Therapeutic Class, 2015-2026 (USD Million)

TABLE Asia Pacific Thalassemia market, by End Use, 2015-2026 (USD Million)

TABLE Latin America Thalassemia market, by Country, 2015-2026 (USD Million)

TABLE Latin America Thalassemia market, by Thalassemia Type, 2015-2026 (USD Million)

TABLE Latin America Thalassemia market, by Therapeutic Class, 2015-2026 (USD Million)

TABLE Latin America Thalassemia market, by End Use, 2015-2026 (USD Million)

TABLE Middle East and Africa Thalassemia market, by Country, 2015-2026 (USD Million)

TABLE Middle East and Africa Thalassemia market, by Thalassemia Type, 2015-2026 (USD Million)

TABLE Middle East and Africa Thalassemia market, by Therapeutic Class, 2015-2026 (USD Million)

TABLE Middle East and Africa Thalassemia market, by Distribution Channel, 2015-2026 (USD Million)

List Of Figures, Charts and Diagrams in Thalassemia Market, By Thalassemia Type (Alpha and Beta), By Therapeutic Class (Iron Chelating Drugs, Blood Transfusion, Gene Therapy, Folic Acid Supplements), By End Use (Hospital, Laboratories, Research Institute, Clinics), and By Geography (EU, NA, APAC, LATAM, and MEA) – Analysis, Size, Share, Trends, & Forecast from 2020-2026

List of Figures

FIGURE Thalassemia market segmentation

FIGURE Market Research Methodology

FIGURE Value chain analysis

FIGURE Porter's Five Forces Analysis

FIGURE Market Attractiveness Analysis

FIGURE COVID-19 Impact Analysis

FIGURE Pre & Post COVID-19 Impact Comparison Study

FIGURE Competitive Landscape; Key company market share analysis, 2018

FIGURE Thalassemia Type segment market share analysis, 2019 & 2026

FIGURE Thalassemia Type segment market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Alpha Thalassemia market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Beta Thalassemia market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Therapeutic Class segment market share analysis, 2019 & 2026

FIGURE Therapeutic Class segment market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Iron Chelating Drugs market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Exjade/Jadenu (deferasirox) market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Blood Transfusions market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Folic Acid Supplements market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Gene Therapy market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE LentiGlobin market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE End Use segment market share analysis, 2019 & 2026

<https://www.bioportfolio.co.uk/product/270627>
bioportfolio97@gmail.com to order

FIGURE End Use segment market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Hospital market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Laboratories market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Research Institutes market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Clinics market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Regional segment market share analysis, 2019 & 2026

FIGURE Regional segment market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE North America Thalassemia market share and leading players, 2018

FIGURE Europe Thalassemia market share and leading players, 2018

FIGURE Asia Pacific Thalassemia market share and leading players, 2018

FIGURE Latin America Thalassemia market share and leading players, 2018

FIGURE Middle East and Africa Thalassemia market share and leading players, 2018

FIGURE North America Thalassemia market share analysis by country, 2018

FIGURE U.S. Thalassemia Market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Canada Thalassemia Market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Europe Thalassemia Market share analysis by country, 2018

FIGURE Germany Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Spain Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Italy Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE UK Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE FranceThalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Rest of the Europe Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Asia Pacific Thalassemia market share analysis by country, 2018

FIGURE India Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE China Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Japan Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE South Korea Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Singapore Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Rest of APACThalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Latin America Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Latin AmericaThalassemia market share analysis by country, 2018

FIGURE Brazil Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Mexico Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Argentina Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Rest of LATAM Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Middle East and Africa Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Middle East and Africa Thalassemia market share analysis by country, 2018

FIGURE Saudi Arabia Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE United Arab Emirates Thalassemia market size, forecast and trend analysis, 2015 to 2026 (USD Million)

How to Buy...

Thalassemia Market, By Thalassemia Type (Alpha and Beta), By Therapeutic Class (Iron Chelating Drugs, Blood Transfusion, Gene Therapy, Folic Acid Supplements), By End Use (Hospital, Laboratories, Research Institute, Clinics), and By Geography (EU, NA, APAC, LATAM, and MEA) – Analysis, Size, Share, Trends, & Forecast from 2020-2026

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/270627>

Option 2 - Request a Proforma Invoice

Fill in the details below, and **Scan** this page **and email** it to us at bioportfolio97@gmail.com We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$3250** | Single User Price
- \$4650** | Site License Price
- \$5650** | Global License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.